Prognostic and predictive markers of systemic sclerosis-interstitial lung disease in a clinical trial and long-term observational cohort

By sjmartinez • May 26, 2023

Ghuman A, Khanna D, Lin CJF, Furst DE, Raghu G, Martinez FJ, Zucchetto M, Huang S, Jennings A, Nihtyanova SI, Denton CP. Prognostic and predictive markers of systemic sclerosis-interstitial lung disease in a clinical trial and long-term observational cohort. Rheumatology (Oxford). 2023 May 25:kead234. doi: 10.1093/rheumatology/kead234. Epub ahead of print. PMID: 37228011.

Tags: Autoantigens and autoantibodies, biological therapies, biomarkers, cytokines and inflammatory mediators, interstitial lung disease, Publications, Rheumatology, scleroderma and related disorders, systemic sclerosis

Comparing Changes in FDG-PET Activity in Sarcoidosis to Changes in Pulmonary Function Tests

Soo Hoo GW, Chang MR, Sather CC. Comparing Changes in FDG-PET Activity in Sarcoidosis to Changes in Pulmonary Function Tests. Arch Bronconeumol. 2024 Dec 5:S0300-2896(24)00452-6.[...]

CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial

Oliai C, Park S, Damon LE, Jonas BA, Jeyakumar D, Wieduwilt MJ, Logan AC, Callas B, Hannigan CA, Gaut DL, Schiller GJ. CPX-351 plus gemtuzumab[...]

Decreases in hemoglobin and hematocrit may signal degree of hemorrhagic shock: retrospective evaluation in a dog model

Jahr JS, Dang J, Tong A, Iskandar S, Patel A, Grogan T, Hopster K, Driessen B, Gunther RA. Decreases in hemoglobin and hematocrit may signal[...]